New Hope for Severe Sinusitis Sufferers with Nasal Polyps

Chronic sinusitis affects more than one in ten people in Germany. The condition is also common across other Western nations, with prevalence rates reaching up to 12 percent. For those suffering from severe cases with nasal polyps, a new treatment option has emerged alongside traditional therapies. The condition often worsens when nasal polyps develop, leading to persistent symptoms. Known risk factors include allergies, asthma, and intolerance to painkillers. Standard treatments involve topical or oral glucocorticoids, as well as surgery to remove polyps.

Recently, dupilumab—a monoclonal antibody—has been approved for patients with chronic sinusitis and nasal polyposis. This drug works by blocking cytokines IL-4 and IL-13, which drive type 2 inflammation. While the stepped-care approach remains the primary treatment method, dupilumab provides an additional option for severe or recurrent cases. The German Society for Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC), representing over 5,000 specialists, continues to monitor advancements in treatment strategies.

Dupilumab’s approval offers a new choice for patients struggling with difficult-to-treat sinusitis. Alongside existing therapies, it targets inflammation more precisely. This development may improve outcomes for those who do not respond well to conventional treatments.